Hoxworth Blood Center welcomes new chief financial officer/executive doctor of business administration
Hoxworth Blood Center, University of Cincinnati, is pleased to announce the appointment of new chief financial officer/executive doctor of business administration (CFO/EDBA), Nick Leibold, MBA.
Leibold comes to Hoxworth after a financial career in highly prestigious investment, financial and pharmaceutical corporations in New York and work as a successful chief financial officer and co-chief executive officer of a pharmaceutical company with employees and operations across 40+ states.
“Mr. Leibold’s expertise will help us support and strengthen the services we provide to patients and donors in the Tri-State,” states Hoxworth director, José Cancelas, MD, PhD. “He brings many attributes to the senior leadership of Hoxworth and will play a key role in our strategic efforts going forward.”
Leibold, a Cincinnati native, earned his B.S. in Finance from Miami University and his MBA from the Stern School of Business of New York University.
Hoxworth Blood Center welcomed Leibold’s arrival on March 27, 2023.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.
Combination immunotherapy helps overcome melanoma treatment resistance
November 10, 2025
MSN highlighted research led by the University of Cincinnati Cancer Center's Trisha Wise-Draper showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.